Biohit Oyj Stock Exchange Release March 20, 2014 at 9:30 a.m. local time (EET)
New B-share subscriptions, total 15.000 pcs, based on the company's stock option program II 2013 approved by the Board of Directors of Biohit Oyj, have been entered into the trade register today. The share subscription price was three (3) euros per share. The nominal value of the share, 2.550 euros, will be recorded in equity and the rest (42.450 euros) in the invested unrestricted equity fund.
After the subscriptions (15.000 shares), the number of all Biohit Oyj's shares will rise into 13.825.593 shares (13.810.593) and B-shares will rise into 10.850.093 shares (10.835.093). The company's share capital will increase to 2,350,350.81 euros to from 2,347,800.81 euros.
The new shares will correspond to a percentage of 0.1% of the Biohit Oyj's total number of shares and 0.02% of the share of voting rights after registration.
Biohit Oyj has applied for the listing of its new shares on the NASDAQ OMX Helsinki in the same series as the company's existing shares. The new shares will be listed on March 21, 2014.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com.